Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency of infarct-related coronary arteries in 81 patients
- PMID: 1520647
- DOI: 10.1007/BF00054184
Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency of infarct-related coronary arteries in 81 patients
Abstract
This open study compared the efficacy and side effects of two dose regimens of intravenous rt-PA initiated before the fifth hour after the onset of myocardial infarction. The first 40 patients (group A) received 1 mg/kg of rt-PA infused over 90 minutes, including a 10-mg initial bolus. The following 41 patients (group B) received 1.5 mg/kg (20-mg initial bolus, 60% over 60 minutes and 40% over 120 minutes). Noninvasive clinical, electrocardiographic, and biochemical parameters of reperfusion were recorded systematically, along with serial measurements of fibrinogen and hemoglobin levels. Coronary arteriography and left ventriculography were performed at the 48th hour or earlier, on an emergency basis, in the absence of signs of reperfusion, or if there were clinical and ECG signs of rethrombosis. Patency of the infarct-related artery (TIMI grades 2 and 3) was achieved in 55% of the group A patients vs. 83% of the group B patients (p less than .01). Twelve emergency coronary arteriographies were performed in each group. No significant difference was observed in the ejection fraction (48% in group A vs. 52% in group B). The peak CPK level was similar in both groups, but the peak occurred earlier in group B (p less than .001). There was no statistically significant difference between the two dose regimens in terms of reduction in fibrinogen or plasminogen levels. Two deaths occurred in group A vs. one death in group B. No cerebrovascular accidents occurred in either group.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Patency trials with reteplase (r-PA): what do they tell us?Am J Cardiol. 1996 Dec 19;78(12A):16-9. doi: 10.1016/s0002-9149(96)00738-2. Am J Cardiol. 1996. PMID: 8990406 Review.
-
More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.Circulation. 1995 Jun 1;91(11):2725-32. doi: 10.1161/01.cir.91.11.2725. Circulation. 1995. PMID: 7758177 Clinical Trial.
-
A randomized dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters.Eur Heart J. 1990 Aug;11(8):730-9. doi: 10.1093/oxfordjournals.eurheartj.a059788. Eur Heart J. 1990. PMID: 2118853 Clinical Trial.
-
Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).J Am Coll Cardiol. 1992 Apr;19(5):885-91. doi: 10.1016/0735-1097(92)90265-o. J Am Coll Cardiol. 1992. PMID: 1552106 Clinical Trial.
-
New developments in thrombolytic therapy.Adv Exp Med Biol. 1990;281:333-54. Adv Exp Med Biol. 1990. PMID: 2129372 Review.
Cited by
-
Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.Drugs. 1995 Jul;50(1):102-36. doi: 10.2165/00003495-199550010-00008. Drugs. 1995. PMID: 7588083 Review.
-
Pharmacokinetic optimisation of the treatment of embolic disorders.Clin Pharmacokinet. 1995 Jan;28(1):67-92. doi: 10.2165/00003088-199528010-00006. Clin Pharmacokinet. 1995. PMID: 7712662 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical